Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC cut its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 232,909 shares of the company’s stock after selling 8,183 shares during the period. ArrowMark Colorado Holdings LLC owned 0.41% of Structure Therapeutics worth $6,316,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GPCR. ANTIPODES PARTNERS Ltd increased its position in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock valued at $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after acquiring an additional 1,122 shares in the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $40,000. Virtus ETF Advisers LLC boosted its stake in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares in the last quarter. Finally, Assetmark Inc. grew its position in Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock worth $62,000 after purchasing an additional 953 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

GPCR has been the subject of several research reports. Citigroup initiated coverage on shares of Structure Therapeutics in a research note on Friday. They set a “buy” rating and a $60.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price for the company. Finally, William Blair initiated coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $78.63.

Structure Therapeutics Trading Down 0.9 %

Structure Therapeutics stock opened at $27.09 on Friday. The firm has a market cap of $1.55 billion, a PE ratio of -36.61 and a beta of -1.35. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74. The stock’s 50 day simple moving average is $20.52 and its two-hundred day simple moving average is $27.38.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. On average, equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.